{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T05:22:38Z","timestamp":1776403358162,"version":"3.51.2"},"reference-count":21,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,22]],"date-time":"2022-08-22T00:00:00Z","timestamp":1661126400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Asia"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.jacasi.2022.08.004","type":"journal-article","created":{"date-parts":[[2022,8,27]],"date-time":"2022-08-27T07:29:02Z","timestamp":1661585342000},"page":"882-893","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Rivaroxaban Monotherapy in Atrial\u00a0Fibrillation and Stable Coronary Artery Disease Across Body Mass Index\u00a0Categories"],"prefix":"10.1016","volume":"2","author":[{"given":"Masanobu","family":"Ishii","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichi","family":"Kaikita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Yasuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaharu","family":"Akao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junya","family":"Ako","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuya","family":"Matoba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masato","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsumi","family":"Miyauchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuhisa","family":"Hagiwara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuo","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Hirayama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kunihiko","family":"Matsui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hisao","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenichi","family":"Tsujita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.jacasi.2022.08.004_bib1","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1056\/NEJMoa1904143","article-title":"AFIRE Investigators. Antithrombotic therapy for atrial fibrillation with stable coronary disease","volume":"381","author":"Yasuda","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.jacasi.2022.08.004_bib2","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","volume":"42","author":"Hindricks","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacasi.2022.08.004_bib3","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.ijcard.2018.04.131","article-title":"Atrial fibrillation and ischemic events with rivaroxaban in patients with stable coronary artery disease (AFIRE): protocol for a multicenter, prospective, randomized, open-label, parallel group study","volume":"265","author":"Yasuda","year":"2018","journal-title":"Int J Cardiol"},{"issue":"4","key":"10.1016\/j.jacasi.2022.08.004_bib4","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1002\/rth2.12146","article-title":"Peak plasma concentration of direct oral anticoagulants in obese patients weighing over 120 kilograms: a retrospective study","volume":"2","author":"Piran","year":"2018","journal-title":"Res Pract Thromb Haemost"},{"issue":"6","key":"10.1016\/j.jacasi.2022.08.004_bib5","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1111\/jth.13323","article-title":"Use of the direct oral anticoagulants in obese patients: guidance from the SSC of the ISTH","volume":"14","author":"Martin","year":"2016","journal-title":"J\u00a0Thromb Haemost"},{"issue":"16","key":"10.1016\/j.jacasi.2022.08.004_bib6","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1093\/eurheartj\/ehy136","article-title":"The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation","volume":"39","author":"Steffel","year":"2018","journal-title":"Eur Heart J"},{"issue":"4","key":"10.1016\/j.jacasi.2022.08.004_bib7","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients","volume":"3","author":"Schulman","year":"2005","journal-title":"J\u00a0Thromb Haemost"},{"issue":"5","key":"10.1016\/j.jacasi.2022.08.004_bib8","first-page":"649","article-title":"Outcomes of direct oral anticoagulants in atrial fibrillation patients across different body mass index categories","volume":"7","author":"Barakat","year":"2021","journal-title":"J\u00a0Am Coll Cardiol EP"},{"issue":"1","key":"10.1016\/j.jacasi.2022.08.004_bib9","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s40256-019-00362-4","article-title":"Efficacy and safety of direct oral anticoagulants versus warfarin in patients with atrial fibrillation across BMI categories: a systematic review and meta-analysis","volume":"20","author":"Zhou","year":"2020","journal-title":"Am J Cardiovasc Drugs"},{"issue":"5","key":"10.1016\/j.jacasi.2022.08.004_bib10","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1161\/CIRCULATIONAHA.118.036768","article-title":"Open-label randomized trial comparing oral anticoagulation with and without single antiplatelet therapy in patients with atrial fibrillation and stable coronary artery disease beyond 1 year after coronary stent implantation","volume":"139","author":"Matsumura-Nakano","year":"2019","journal-title":"Circulation"},{"issue":"11","key":"10.1016\/j.jacasi.2022.08.004_bib11","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.120.010476","article-title":"Bleeding and subsequent cardiovascular events and death in atrial fibrillation with stable coronary artery disease: insights from the AFIRE trial","volume":"14","author":"Kaikita","year":"2021","journal-title":"Circ Cardiovasc Interv"},{"issue":"14","key":"10.1016\/j.jacasi.2022.08.004_bib12","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1016\/j.jacc.2015.01.047","article-title":"Association of spontaneous bleeding and myocardial infarction with long-term mortality after percutaneous coronary intervention","volume":"65","author":"Kazi","year":"2015","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.jacasi.2022.08.004_bib13","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s12928-017-0459-8","article-title":"Prasugrel for Japanese patients with acute coronary syndrome in short-term clinical practice (PRASFIT-Practice I): a postmarketing observational study","volume":"33","author":"Nakamura","year":"2018","journal-title":"Cardiovasc Interv Ther"},{"issue":"14","key":"10.1016\/j.jacasi.2022.08.004_bib14","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.4244\/EIJ-D-20-00345","article-title":"High bleeding risk and clinical outcomes in East Asian patients undergoing percutaneous coronary intervention: the PENDULUM registry","volume":"16","author":"Nakamura","year":"2021","journal-title":"EuroIntervention"},{"key":"10.1016\/j.jacasi.2022.08.004_bib15","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.amjcard.2021.07.041","article-title":"Impact of low body mass index on features of coronary culprit plaques and outcomes in patients with acute coronary syndrome","volume":"158","author":"Kobayashi","year":"2021","journal-title":"Am J Cardiol"},{"issue":"9","key":"10.1016\/j.jacasi.2022.08.004_bib16","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1093\/cvr\/cvaa263","article-title":"Pleiotropic actions of factor Xa inhibition in cardiovascular prevention: mechanistic insights and implications for anti-thrombotic treatment","volume":"117","author":"ten Cate","year":"2021","journal-title":"Cardiovasc Res"},{"issue":"4","key":"10.1016\/j.jacasi.2022.08.004_bib17","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1161\/CIRCRESAHA.119.315099","article-title":"Rivaroxaban reduces arterial thrombosis by inhibition of FXa-driven platelet activation via protease activated receptor-1","volume":"126","author":"Petzold","year":"2020","journal-title":"Circ Res"},{"issue":"3","key":"10.1016\/j.jacasi.2022.08.004_bib18","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s00380-016-0864-4","article-title":"Evaluation of the antithrombotic abilities of non-vitamin K antagonist oral anticoagulants using the Total Thrombus-formation Analysis\u00a0System(\u00ae)","volume":"32","author":"Idemoto","year":"2017","journal-title":"Heart Vessels"},{"issue":"21","key":"10.1016\/j.jacasi.2022.08.004_bib19","doi-asserted-by":"crossref","first-page":"e984","DOI":"10.1161\/CIR.0000000000000973","article-title":"Obesity and cardiovascular disease: a scientific statement from the American Heart Association","volume":"143","author":"Powell-Wiley","year":"2021","journal-title":"Circulation"},{"issue":"13","key":"10.1016\/j.jacasi.2022.08.004_bib20","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/j.jcin.2017.03.013","volume":"10","author":"Holroyd","year":"2017","journal-title":"J\u00a0Am Coll Cardiol Intv"},{"issue":"1","key":"10.1016\/j.jacasi.2022.08.004_bib21","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2133\/dmpk.DMPK-12-RG-034","article-title":"Model-based dose selection for phase III rivaroxaban study in Japanese patients with non-valvular atrial fibrillation","volume":"28","author":"Tanigawa","year":"2013","journal-title":"Drug Metab Pharmacokinet"}],"container-title":["JACC: Asia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772374722002174?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772374722002174?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T09:58:45Z","timestamp":1757411925000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772374722002174"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":21,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["S2772374722002174"],"URL":"https:\/\/doi.org\/10.1016\/j.jacasi.2022.08.004","relation":{},"ISSN":["2772-3747"],"issn-type":[{"value":"2772-3747","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rivaroxaban Monotherapy in Atrial\u00a0Fibrillation and Stable Coronary Artery Disease Across Body Mass Index\u00a0Categories","name":"articletitle","label":"Article Title"},{"value":"JACC: Asia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacasi.2022.08.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}]}}